REGORAFENIB AFTER FAILURE OF GEMCITABINE AND PLATINUM-BASED CHEMOTHERAPY FOR LOCALLY ADVANCED (NON RESECTABLE) AND METASTATIC INTRA-HEPATIC OR HILAR CHOLANGIOCARCINOMA: A Randomized Double-blinded Phase II Trial.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 May 2019
Price : $35 *
At a glance
- Drugs Regorafenib (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- Acronyms REACHIN
- 31 May 2019 Results of exploratory analysis published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 19 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 19 Mar 2019 Planned End Date changed from 1 Dec 2016 to 1 Jun 2020.